10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
German clinical-stage biopharma company Affimed has announced a plan to focus its research and development investments on advancing on-going and previously announced clinical trials for its innate cell engager candidates, AFM13 and AFM24. 23 May 2019
Oncology heavyweight Robin Taylor has made the switch from VP level at big pharma to chief commercial officer at an emerging, multi-product biotech company. 23 May 2019
Tokyo-based Chugai Pharmaceutical is to close two research centers and transfer their functions to a new facility that it will build in Yokohama. 23 May 2019
ElevateBio, a newly-launched cell and gene therapy incubator, has announced that AlloVir, formerly known as ViraCyte, has joined its fledgling portfolio. 23 May 2019
It’s ASCO time again. The annual meeting of the American Society of Clinical Oncology (ASCO) is now almost upon us, with the event due to start in Chicago on Friday, May 31. 22 May 2019
Less than a year after Japanese drugmaker Takeda’s Entyvio was approved in the company’s home country to treat ulcerative colitis, a further indication for the drug has been authorized. 22 May 2019
Amgen today offered to acquire all the shares of its research partner, Copenhagen, Denmark-headquartered Nuevolution, for a consideration of 32.50 Swedish kronor in cash per share. 22 May 2019
Russia’s first original drug for the treatment of severe psoriasis has been registered by one of the leading local drugmakers Biocad, according to the company. 22 May 2019
US pharma giant Merck & Co announced yesterday that it will acquire privately held Peloton Therapeutics in a deal which could exceed $2.2 billion, and which would bring the company a late-stage kidney cancer candidate. 22 May 2019
Merck & Co’s Keytruda (pembrolizumab) is the world’s top-selling immuno-oncology drug with approvals across 12 different cancer types, but even it cannot help in the metastatic triple-negative breast cancer (TNBC) setting. 21 May 2019
At the ATS International Conference, the New Jersey, USA-based rare disease specialist Insmedmhas presented new data from the ongoing Phase III CONVERT study. 21 May 2019
German biotech Evotec has bought Seattle, USA-based Just Biotherapeutics for up to $90 million, including performance-based payments over the next three years. The initial consideration upon closing is $ 60 million. 21 May 2019
STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec, and Dizal Pharmaceutical, a biotechnology company, today announced a strategic partnership. 21 May 2019
Ocular Therapeutix (Nasdaq: OCUL) late Monday announced top-line results from the first pivotal Phase III clinical trial of OTX-TP, which failed to meet primary endpoint but achieved statistically-significant reduction of intraocular pressure versus placebo. 21 May 2019
As China is becoming an incubator for an increasing number of innovative biotech startups, multinationals are actively seeking potential novel assets to enrich their global pipelines, said speakers at the ChinaBio forum held recently in Shanghai, reports The Pharma Letter’s local correspondent Wang Fangqing. 20 May 2019
Actelion, one of the Janssen companies of Johnson & Johnson, presented new data on its pulmonary drug yesterday at the American Thoracic Society (ATS) conference 2019. 20 May 2019
Belgian biopharma UCB started the week by announcing that the US Food and Drug Administration (FDA) approval of Nayzilam (midazolam) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy. 20 May 2019
Actelion, the Swiss biotech firm acquired by Johnson & Johnson’s Janssen unit in a $30 billion deal in 2017, has entered into a collaboration with UK-based Owlstone Medical. 20 May 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024